FOGHORN THERAPEUTICS Reports Record Earnings for Q2 of FY2023
🌥️Earnings Overview For FY2023 Q2, FOGHORN THERAPEUTICS ($NASDAQ:FHTX) reported total revenue of USD 5.6 million, a 24.7% increase from the [...]
Foghorn Therapeutics Shares Soar 18% After FDA Lifts Clinical Hold on Phase 1 Trial
☀️Trending News Foghorn Therapeutics ($NASDAQ:FHTX) is a biotechnology firm dedicated to the development of novel therapies for genetic diseases. Today, [...]
Foghorn Therapeutics Intrinsic Stock Value – Market Sentiment High on Foghorn Therapeutics Stock Ahead of Friday
Trending News 🌥️ Foghorn Therapeutics ($NASDAQ:FHTX) Inc. is an innovative biotechnology company focused on developing novel therapies for cancer and [...]
Foghorn Therapeutics Reports Impressive Quarter Despite Negative EPS
Trending News ☀️ Foghorn Therapeutics ($NASDAQ:FHTX) recently reported its earnings for the quarter, and despite a negative GAAP EPS of [...]
Foghorn Therapeutics Stock Fair Value – Foghorn Therapeutics Shares Plunge Following FDA Setback on Cancer Drug Trial
Trending News 🌧️ Foghorn Therapeutics ($NASDAQ:FHTX) is an American biotechnology company that develops novel treatments for cancer and serious diseases. [...]
presently covering the company.
Trending News ☀️ Foghorn Therapeutics ($NASDAQ:FHTX) Inc. is a biotechnology company dedicated to developing innovative therapies for cancer, rare diseases, [...]
Foghorn Therapeutics (FHTX+) Expects High Returns On Capital Employed in 2023
Trending News 🌥️ Foghorn Therapeutics ($NASDAQ:FHTX) (NASDAQ:FHTX) is a biotechnology company focused on discovering and developing treatments for cancer and [...]
Foghorn Therapeutics Experiences 5.9% Increase in Short Interest in 2023
Trending News ☀️ Foghorn Therapeutics ($NASDAQ:FHTX) Inc. experienced a notable increase in short interest in 2023. Over the last month, [...]
Investors in Foghorn Therapeutics Lose 21% Over Last Year
Trending News 🌧️ Foghorn Therapeutics Intrinsic Value – Investors in Foghorn Therapeutics($NASDAQ:FHTX) have unfortunately lost 21% over the last year. [...]
